Overview

A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids

Status:
Not yet recruiting
Trial end date:
2028-02-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of two different doses of ianalumab added to eltrombopag to prolong Time to Treatment Failure (TTF) in adults with primary ITP who failed previous first-line treatment with steroids.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals